Geron’s Sharp Decline: Why Investors Should Question the Telomerase Bet
Geron’s steep price slide shows why clinical‑stage biotech stocks risk panic; investors see a fragile outlook amid stalled trials and limited revenue paths.
3 minutes to read
GERON CORP
Geron’s Share Slide Highlights Biotech Volatility and Investor Alarm
Geron’s stock dives 6.45% as investors question the future of its telomerase drug, highlighting thin liquidity and stiff competition from peers.
3 minutes to read
Geron Shares Rise as New Talent Incentives Boost Imetelstat Pipeline Momentum
Geron’s recent 3.3% stock rise, driven by 570k new option grants, signals confidence in its telomerase drug imetelstat and a potential upside from upcoming milestones.
3 minutes to read